Education
Oral Abstract Schedule
Thursday, September 24, 2026
Resident Oral Abstract Schedule
Sponsored by:
| Day/Time | Presenter | Abstract Title |
|---|---|---|
| Thursday 2:15 pm | Laura Alfino | Abscess formation in dogs undergoing cytotoxic chemotherapy for lymphoma |
| Thursday 2:30 pm | Marissa Goodwin | Randomized double-blinded placebo-controlled clinical trial of metronidazole for managing chemotherapy-induced diarrhea in dogs |
| Thursday 2:45 pm | Rachel Uyehara | Plasma amino acid profile in dogs with multicentric lymphoma undergoing multi-agent chemotherapy |
| Thursday 3:30 pm | Letty Bonilla | Safety and tolerability evaluation of combination doxorubicin and a novel oil-blended formulation of rapamycin (RapaBoil) in dogs with surgically excised, stage II splenic hemangiosarcoma |
| Thursday 3:45 pm | Natrine Cheuk | Integrin α5β1as a potential target for enhancing vulnerability of canine hemangiosarcoma to doxorubicin |
| Thursday 4:00 pm | Nicholle Ross | Effects of metronomic chlorambucil on regulatory T cells and tumor vasculature in dogs with soft tissue sarcoma |
| Thursday 4:15 pm | Zachary Yaufman | First-in-patient study of a novel PD-L1 FC-fusion immunotherapeutic vaccine in dogs with carcinoma or sarcoma |
| Thursday 4:30 pm | Anett Szczepanek | Minimal toxicity and potential early efficacy in phase 1 trial in dogs with pulmonary metastasis treated with anti-canine PD-L1 antibody (JC071C) |
| Thursday 4:45 pm | Lauren Darwin | Observations and clinical utility of 18F-FDG PET/CT in veterinary oncology: early experience at a single academic institution |
Friday, September 25, 2026 – Saturday, September 26, 2026
General Oral Abstract Schedule
Sponsored by:
| Day/Time | PRESENTER | ABSTRACT TITLE |
|---|---|---|
| Friday 1:15 pm | Guannan Wang | Diagnostic utility of comprehensive genomic profiling in canine cancers |
| Friday 1:30 pm | Josephine Tsang | A blood-based classifier for differential diagnosis of feline IBD and enteropathy-associated T-cell lymphoma |
| Friday 1:45 pm | Luke Borst | Artificial intelligence-assisted mitotic counts improve efficiency, accuracy, and inter-pathologist agreement |
| Friday 2:00 pm | Nicola Mason | Checkmate K9: A first in dog combination anti CTLA 4 plus anti PD 1 immunotherapy trial in canine solid tumors |
| Friday 2:15 pm | Amy LeBlanc | Multiomic profiling of canine osteosarcoma reveals prognostic alterations with therapeutic and translational relevance for humans |
| Friday 2:30 pm | Latasha Ludwig | Recognition and reporting of histologic features in canine integumentary mast cell tumors is highly variable amongst pathologists |
| Friday 2:45 pm | Heather Gardner | Response to combination immune checkpoint inhibitor therapy in metastatic canine osteosarcoma is associated with plasma methylome signatures from memory T-cells |
| Saturday 3:15 pm | Thomas Cherpes | Developing a novel chimeric anti-canine CD40 agonistic antibody as therapy for T-cell lymphoma |
| Saturday 3:30 pm | Matheus Moreno Passos Barbosa | CD45-targeted cytokine therapy in canine oral malignant melanoma: A translational pilot study |
| Saturday 3:45 pm | Matthew Berry | Development and pilot clinical evaluation of a personalized extracellular vesicle vaccine for canine osteosarcoma |
| Saturday 4:00 pm | Elise Weir | Canine transmissible venereal tumor (CTVT) exhibits a germline-like transcriptional program associated with immune evasion |
| Saturday 4:15 pm | Saghar Kaabinejadian | Dog and human leukocyte antigens are functional homologs and present identical peptides from tumor antigens |
| Saturday 4:30 pm | Shay Curry | JAK inhibitor therapy for indolent feline T-cell neoplasms |
| Saturday 4:45 pm | Kim Selting | Comparison of two hypofractionated radiation protocols combined with anti-PD-1 canine monoclonal antibody to treat oligometastatic lung cancer |